Jun Qiu, Youhong Li, Yuan Zhong, Xi Yang, Wang Bingyu, Xinyi Sun, Fu Yin, Kedan Cen, Lian Jiangfang, Jianqing Zhou
Medicine School of Ningbo University, Ningbo, China.
Li Huili Hospital Affiliated to Ningbo University, Ningbo, China.
Front Cardiovasc Med. 2022 Dec 7;9:1022988. doi: 10.3389/fcvm.2022.1022988. eCollection 2022.
Endothelial-mesenchymal transition (EndMT) is a differentiation process in which endothelial cells lose their own characteristics and acquire mesenchymal-like characteristics, which contributes to the formation and development of atherosclerotic plaques. Until now, there is still a lack of effective measures to treat atherosclerosis (AS), so there is an urgent need to understand the underlying mechanisms of AS. In addition, although various studies have shown that EndMT is involved in the pathological stages of cardiovascular diseases, such as myocardial fibrosis, myocardial hypertrophy, and hypertension, the specific molecular mechanisms driving EndMT are still in the exploratory stage. In this review, we review the role of histone modifications (methylation, demethylation and acetylation, deacetylation) on EndMT in cardiovascular disease, aiming to target histone-modifying enzymes to guide cardiovascular disease therapy.
内皮-间充质转化(EndMT)是一种分化过程,在此过程中内皮细胞丧失自身特性并获得间充质样特性,这有助于动脉粥样硬化斑块的形成和发展。到目前为止,仍缺乏治疗动脉粥样硬化(AS)的有效措施,因此迫切需要了解AS的潜在机制。此外,尽管各种研究表明EndMT参与心血管疾病的病理阶段,如心肌纤维化、心肌肥大和高血压,但驱动EndMT的具体分子机制仍处于探索阶段。在这篇综述中,我们回顾了组蛋白修饰(甲基化、去甲基化以及乙酰化、去乙酰化)在心血管疾病中EndMT上的作用,旨在以组蛋白修饰酶为靶点来指导心血管疾病的治疗。